GNLX

+ Watchlist + Portfolio

Genelux Corp.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $2.68
52-Week Range: $2.29 – $8.54
Market Cap: $123.97M
P/E (TTM): —
EPS (TTM): -0.86
Dividend Yield: —

Advanced Metrics

Price/Book: 7.68
PEG Ratio: —
Return on Equity: -177.93%
Return on Assets: -77.89%
Gross Margin: 100.00%
Operating Margin: -455275.00%
Profit Margin: 0.00%
Current Ratio: 2.39
Debt/Equity: 0.15
Total Debt: $2.42M
Free Cash Flow: $-16.29M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $105.01M

GNLX Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$11.07M	$170.00K	$8.00K	$8.00K
Research & Development	$9.08M	$12.77M	$19.00M	$19.85M
Selling, General & Admin	$5.00M	$11.57M	$12.71M	$13.37M
Operating Expenses	$14.08M	$24.34M	$31.70M	$33.22M
Operating Income	-$3.01M	-$24.16M	-$31.70M	-$33.21M
EBITDA	-$1.73M	-$26.46M	-$30.79M	-$32.64M
Pretax Income	-$4.11M	-$28.30M	-$29.87M	-$32.15M
Income Tax	$1.10M	$0.00	—	—
Net Income	-$5.21M	-$28.30M	-$29.87M	-$32.15M
Diluted EPS	-0.22	-1.16	-0.95	-0.86
Diluted Shares	23.65M	24.43M	31.45M	37.18M

GNLX Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$397.00K	$9.42M	$8.56M	$5.33M
Current Assets	$1.89M	$24.20M	$31.55M	$15.13M
Total Assets	$5.53M	$27.89M	$34.72M	$19.03M
Current Liabilities	$31.63M	$6.55M	$6.90M	$6.22M
Long-Term Debt	$8.52M	—	—	—
Total Debt	$26.35M	$2.52M	$1.87M	$1.69M
Total Liabilities	$41.31M	$8.42M	$8.44M	$7.48M
Retained Earnings	-$189.78M	-$221.52M	-$251.39M	-$283.54M
Shareholders' Equity	-$35.78M	$19.47M	$26.27M	$11.54M
Working Capital	-$29.73M	$17.65M	$24.64M	$8.90M
Net Debt	$24.53M	—	—	—

GNLX Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$3.57M	-$20.27M	-$21.23M	-$25.27M
Capital Expenditure	-$49.00K	-$1.02M	-$381.00K	-$1.10M
Free Cash Flow	-$3.62M	-$21.30M	-$21.61M	-$26.37M
Depreciation & Amortisation	$968.00K	$1.02M	$903.00K	$574.00K
Stock-Based Compensation	$2.42M	$5.20M	$6.07M	$6.68M
Investing Cash Flow	-$49.00K	-$14.72M	-$8.13M	$12.14M
Financing Cash Flow	-$478.00K	$44.02M	$28.51M	$9.89M
Net Change in Cash	-$4.10M	$9.02M	-$853.00K	-$3.23M

GNLX Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	$0.00	$0.00	$8.00K	$0.00
Research & Development	$4.70M	$4.76M	$4.74M	$5.65M	$5.78M
Selling, General & Admin	$3.12M	$3.03M	$3.45M	$3.77M	$3.39M
Operating Expenses	$7.82M	$7.79M	$8.19M	$9.42M	$9.17M
Operating Income	-$7.82M	-$7.79M	-$8.19M	-$9.41M	-$9.17M
EBITDA	-$7.68M	-$7.65M	-$8.05M	-$9.26M	-$9.07M
Pretax Income	-$7.49M	-$7.46M	-$7.95M	-$9.25M	-$8.93M
Net Income	-$7.49M	-$7.46M	-$7.95M	-$9.25M	-$8.93M
Diluted EPS	-0.21	-0.20	-0.21	—	-0.20
Diluted Shares	34.93M	37.95M	37.89M	—	44.15M

GNLX Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$16.21M	$6.55M	$3.69M	$5.33M	$9.27M
Current Assets	$35.95M	$29.23M	$21.55M	$15.13M	$26.75M
Total Assets	$38.98M	$32.25M	$24.99M	$19.03M	$32.37M
Current Liabilities	$7.69M	$6.99M	$5.13M	$6.22M	$7.27M
Total Debt	$1.79M	$1.71M	$1.62M	$1.69M	$2.50M
Total Liabilities	$9.14M	$8.35M	$6.40M	$7.48M	$9.45M
Retained Earnings	-$258.88M	-$266.34M	-$274.29M	-$283.54M	-$292.47M
Shareholders' Equity	$29.85M	$23.90M	$18.59M	$11.54M	$22.92M
Working Capital	$28.26M	$22.25M	$16.43M	$8.90M	$19.48M

GNLX Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$5.43M	-$7.06M	-$6.58M	-$6.20M	-$6.06M
Capital Expenditure	-$30.00K	-$115.00K	-$517.00K	-$436.00K	-$921.00K
Free Cash Flow	-$5.46M	-$7.17M	-$7.09M	-$6.63M	-$6.98M
Depreciation & Amortisation	$139.00K	$143.00K	$144.00K	$148.00K	$98.00K
Stock-Based Compensation	$1.43M	$1.30M	$2.35M	$1.60M	$1.46M
Investing Cash Flow	$3.51M	-$2.65M	$4.72M	$6.56M	-$8.54M
Financing Cash Flow	$9.57M	$52.00K	$0.00	$276.00K	$18.54M
Net Change in Cash	$7.64M	-$9.66M	-$1.85M	$641.00K	$3.94M

Market Snapshot

About

Genelux Corp. is a clinical-stage biopharmaceutical company developing next-generation oncolytic viral immunotherapies for difficult-to-treat solid tumors. The company's lead product candidate Olvi-Vec is an attenuated vaccinia virus designed to selectively infect and destroy cancer cells while stimulating an anti-tumor immune response. Genelux is advancing multiple clinical programs evaluating Olvi-Vec as monotherapy and in combination with other cancer treatments for various tumor types. The company employs proprietary platform technology to engineer viruses with tumor-selective replication capabilities.